{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:40:35Z","timestamp":1786545635756,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1038\/ajg.2012.325","type":"journal-article","created":{"date-parts":[[2012,11,19]],"date-time":"2012-11-19T04:26:28Z","timestamp":1353299188000},"page":"1726-1729","source":"Crossref","is-referenced-by-count":7,"title":["Editorial: Linaclotide: Promising IBS-C Efficacy in an Era of Provisional Study Endpoints"],"prefix":"10.14309","volume":"107","author":[{"given":"Gregory S","family":"Sayuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20210210","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation.","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-22-20210210","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/14656566.2012.651458","article-title":"Rifaximin for the treatment of irritable bowel syndrome.","volume":"13","author":"Cremonini","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"R4-22-20210210","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2036.2006.02937.x","article-title":"Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndromea European perspective.","volume":"24","author":"Heading","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R5-22-20210210","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2165\/11590690-000000000-00000","article-title":"The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.","volume":"34","author":"Lewis","year":"2011","journal-title":"Drug Saf"},{"key":"R8-22-20210210","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1586\/egh.11.30","article-title":"Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.","volume":"5","author":"Roque","year":"2011","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R10-22-20210210","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ejphar.2010.09.019","article-title":"Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.","volume":"649","author":"Busby","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"R11-22-20210210","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJMoa1010863","article-title":"Two randomized trials of linaclotide for chronic constipation.","volume":"365","author":"Lembo","year":"2011","journal-title":"N Engl J Med"},{"key":"R14-22-20210210","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.lfs.2010.03.015","article-title":"Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.","volume":"86","author":"Bryant","year":"2010","journal-title":"Life Sci"},{"key":"R15-22-20210210","doi-asserted-by":"crossref","first-page":"G942","DOI":"10.1152\/ajpgi.00264.2005","article-title":"Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers.","volume":"290","author":"Camilleri","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R16-22-20210210","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","article-title":"A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.","volume":"161","author":"Camilleri","year":"2001","journal-title":"Arch Int Med"},{"key":"R17-22-20210210","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2036.1999.00610.x","article-title":"Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.","volume":"13","author":"Camilleri","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-22-20210210","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(00)02033-X","article-title":"Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.","volume":"355","author":"Camilleri","year":"2000","journal-title":"Lancet"},{"key":"R19-22-20210210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndromeresults of two randomized, placebo-controlled studies.","volume":"29","author":"Drossman","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-22-20210210","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1572-0241.2006.00535.x","article-title":"Reports of satisfactory relief by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement.","volume":"101","author":"Whitehead","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R21-22-20210210","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1572-0241.2006.00519.x","article-title":"Measuring successful treatment of irritable bowel syndrome: is satisfactory relief enough?","volume":"101","author":"Schoenfeld","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R23-22-20210210","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/030006059802600203","article-title":"Adequate relief as an endpoint in clinical trials in irritable bowel syndrome.","volume":"26","author":"Mangel","year":"1998","journal-title":"J Int Med Res"},{"key":"R24-22-20210210","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1586\/egh.11.13","article-title":"End points in irritable bowel syndrome.","volume":"5","author":"Mangel","year":"2011","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R25-22-20210210","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders.","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"R26-22-20210210","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1365-2036.2010.04464.x","article-title":"Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials.","volume":"32","author":"Spiegel","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R27-22-20210210","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1365-2036.2010.04443.x","article-title":"Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice.","volume":"32","author":"Spiegel","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R31-22-20210210","doi-asserted-by":"crossref","first-page":"s538","DOI":"10.1016\/S0016-5085(11)62229-4","article-title":"A novel role of cyclic GMP in colonic sensory neurotransmission in healthy and TNBS-treated mice.","volume":"140","author":"Castro","year":"2011","journal-title":"Gastroenterology"},{"key":"R32-22-20210210","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1136\/gut.2005.070789","article-title":"A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.","volume":"54","author":"Tack","year":"2005","journal-title":"Gut"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2012325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2012325","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2012325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201211000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:44:22Z","timestamp":1786542262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201211000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2012.325","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}